144 related articles for article (PubMed ID: 6961970)
1. Successful treatment of a patient with acute nonlymphoblastic leukemia (ANLL) and anthracycline cardiomyopathy with 4' (9-acridinylamino) methanesulfon-m-anisidide (AMSA).
Fanucchi MP; Arlin ZA
Cancer Chemother Pharmacol; 1982 Dec; 10(1):27-8. PubMed ID: 6961970
[TBL] [Abstract][Full Text] [Related]
2. Treatment of acute leukemia in relapse with 4'(9-acridinylamino) methanesulfon-m-anisidide (AMSA) in combination with cytosine arabinoside and thioguanine.
Arlin ZA; Flomenberg N; Gee TS; Kempin SJ; Dellaquila C; Mertelsmann R; Straus DJ; Young CW; Clarkson BD
Cancer Clin Trials; 1981; 4(3):317-21. PubMed ID: 6895190
[TBL] [Abstract][Full Text] [Related]
3. 4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia.
Kahn SB; Sklaroff R; Lebedda J; Conroy JF; Bulova S; Brodsky I
Am J Clin Oncol; 1983 Aug; 6(4):493-502. PubMed ID: 6191561
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma.
Tan CT; Hancock C; Steinherz PG; Steinherz LJ; Sorell M; Chan KW; Mondora A; Miller DR
Cancer Res; 1982 Apr; 42(4):1579-81. PubMed ID: 6895864
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of AMSA in children with acute leukemia. A Pediatric Oncology Group study.
Krischer J; Land VJ; Civin CI; Ragab AH; Mahoney DH; Frankel LS
Cancer; 1984 Jul; 54(2):207-10. PubMed ID: 6586277
[TBL] [Abstract][Full Text] [Related]
6. Acridinyl anisidide (m-AMSA) therapy in 11 patients with refractory acute leukemia.
Naparstek E; Shinar E; Polliack A
Isr J Med Sci; 1984 Feb; 20(2):118-22. PubMed ID: 6546740
[TBL] [Abstract][Full Text] [Related]
7. [Case of refractory acute myeloblastic leukemia who achieved complete remission by a new anti-leukemic agent, 4'-(9-acridinylamino) methanesulfon-m-anisidide (AMSA)].
Nagura E; Kawashima K; Suzuki H; Ohno R; Yamada K; Yokomaku S; Ogawa M
Rinsho Ketsueki; 1983 May; 24(5):632-8. PubMed ID: 6577212
[No Abstract] [Full Text] [Related]
8. Treatment of refractory adult lymphoblastic leukemia (ALL) with 4'(9-acridinylamino) methanesulfon-M-anisidide (AMSA).
Arlin ZA; Fanucchi MP; Gee TS; Kempin SJ; Mertelsmann R; Young CW; Clarkson BD
Blood; 1982 Nov; 60(5):1224-6. PubMed ID: 6957250
[TBL] [Abstract][Full Text] [Related]
9. A phase II evaluation of m-AMSA, 4'-(9-acridinylamino) methanesulfon-m-anisidide, in patients with breast cancer.
Currie VE; Howard J; Wittes R
Cancer Clin Trials; 1981; 4(3):249-51. PubMed ID: 6895189
[TBL] [Abstract][Full Text] [Related]
10. Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia.
Arlin ZA; Sklaroff RB; Gee TS; Kempin SJ; Howard J; Clarkson BD; Young CW
Cancer Res; 1980 Sep; 40(9):3304-6. PubMed ID: 6933002
[TBL] [Abstract][Full Text] [Related]
11. Development and cross-resistance characteristics of a subline of P388 leukemia resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide.
Johnson RK; Howard WS
Eur J Cancer Clin Oncol; 1982 May; 18(5):479-87. PubMed ID: 6956514
[No Abstract] [Full Text] [Related]
12. Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) in patients with gastric adenocarcinoma.
Sordillo PP; Magill GB; Gralla RJ; Kelsen DP
Am J Clin Oncol; 1982 Jun; 5(3):273-5. PubMed ID: 6896259
[TBL] [Abstract][Full Text] [Related]
13. Phase II. Trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in the treatment of advanced non-Hodgkin's lymphoma.
Warrell RP; Straus DJ; Young CW
Cancer Treat Rep; 1980; 64(10-11):1157-8. PubMed ID: 6893952
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults.
Legha SS; Keating MJ; McCredie KB; Bodey GP; Freireich EJ
Blood; 1982 Aug; 60(2):484-90. PubMed ID: 6953987
[TBL] [Abstract][Full Text] [Related]
15. Phase II evaluation of m-AMSA (4'-(9-acridinylamino)-methanesulfon-m-anisidide) in patients with adenocarcinoma of the pancreas.
Sternberg CN; Magill GB; Sordillo PP; Cheng E; Currie VE
Am J Clin Oncol; 1983 Aug; 6(4):459-62. PubMed ID: 6688151
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with advanced colorectal carcinoma.
Carroll DS; Kemeny N; Lynch G; Wookcock T
Cancer Treat Rep; 1980; 64(10-11):1149-50. PubMed ID: 6893951
[No Abstract] [Full Text] [Related]
17. Phase II. Evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with advanced sarcoma.
Sordillo PP; Magill GB; Gralla RJ; Golbey RB
Cancer Treat Rep; 1980; 64(10-11):1129-30. PubMed ID: 6893950
[No Abstract] [Full Text] [Related]
18. Phase II evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with non-small cell lung cancer.
Casper ES; Gralla RJ; Kelsen DP; Natale RB; Sordillo P; Houghton A
Cancer Treat Rep; 1980; 64(2-3):345-7. PubMed ID: 6893294
[No Abstract] [Full Text] [Related]
19. Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic renal cell carcinoma.
Van Echo DA; Markus S; Aisner J; Wiernik PH
Cancer Treat Rep; 1980; 64(8-9):1009-10. PubMed ID: 6893810
[No Abstract] [Full Text] [Related]
20. New drugs in the treatment of acute and chronic leukemia with some emphasis on m-AMSA.
Jehn U; Heinemann V
Anticancer Res; 1991; 11(2):705-11. PubMed ID: 2064323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]